ClinicalTrials.gg
CompletedNCT01597492Updated Aug 16, 2018Results posted

A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)

A Phase 4 interventional study of Belimumab plus Early Vaccination and Belimumab plus Late Vaccination in Systemic Lupus Erythematosus, sponsored by Human Genome Sciences Inc., a GSK Company. Completed at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-16.

Sponsored by Human Genome Sciences Inc., a GSK Company (part of GlaxoSmithKline) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
79
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.

Enrollment
22nd of 36
79 · median 81
Started
2012
with 4 others
Phase 4
10 of 36
2 open now
Registered
13th of 36
by date
Lead sponsor
7 of 36
Human Genome Sciences Inc., a GSK Company

Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 22nd largest by enrollment, is one of 5 that started in 2012, is one of 10 in phase 4, and was the 13th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About belimumab

belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing belimumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

The purpose of this study is to assess the impact of belimumab on immune response to pneumococcal vaccine in subjects with Systemic Lupus Erythematosus (SLE).

Read the detailed description

All patients in this study will receive belimumab plus standard therapy for SLE and vaccination against pneumococcus. Patients will be randomized to receive pneumococcal vaccination either 4 weeks prior (early vaccination group) or 24 weeks after (late vaccination group) their first belimumab dose. Vaccine response will be assessed 4 weeks after vaccine administration.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Antibodies
  • Vaccines
  • SLE
  • Immune System Diseases
  • Biological Therapy
  • Autoimmune Diseases
  • Pneumococcal Vaccines
  • Lupus
  • Immunoglobulins
  • Vaccination
  • Belimumab
  • Biological Agents
  • Immunization
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Clinical diagnosis of SLE by American College of Rheumatology (ACR) criteria.
  • Active SLE disease.
  • Autoantibody-positive.
  • Have antibodies with titers >1.0 microgram (mcg)/mL to no more than 9 of the 23 serotypes present in the pneumococcal vaccine.
  • Have the ability to understand the requirements of the study, provide written , and comply with the study protocol procedures.

Key Exclusion Criteria:

  • Pregnant or nursing.
  • Have received any prior treatment with belimumab.
  • Have received a within the past 30 days.
  • Have received a pneumococcal vaccination with the past 5 years.
  • Have a history of severe allergic reaction to a vaccine, contrast agents (such as those used for x-rays and CT scans), or biological medicines.
  • Have required management of an infection or have had infections that keep coming back within the past 60 days.
  • : Serologic evidence of Hepatitis B (HB) infection based on the results of testing for HB surface antigen (HBsAg) and anti-HB core antibody (anti-HBc):

    • Subjects positive for HBsAg are excluded.
    • Subjects negative for HBsAg but positive for anti-HBc, regardless of anti-HBs antibody status, are excluded.
  • : Positive test for Hepatitis C antibody.
  • Known (HIV) infection.
  • Have current drug or alcohol abuse or dependence.
  • Have a Grade 3/4 immunoglobulin (Ig)G deficiency (IgG level \<400 milligrams [mg]/ deciliter [dL]) or IgA deficiency (IgA level \<10 mg/dL).
  • Subjects who have evidence of serious suicide risk including any history of suicidal behavior in the last 6 months and/or suicidal ideation with some intent to act in the last 2 months or who in the investigator's judgment, pose a significant suicide risk.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
79 participants (actual)

Study arms

  • Experimental
    Belimumab plus Early Vaccination

    Belimumab plus Early Vaccination

    Biological: Belimumab plus Early Vaccination

  • Experimental
    Belimumab plus Late Vaccination

    Belimumab plus Late Vaccination

    Biological: Belimumab plus Late Vaccination

Interventions

  • BiologicalBelimumab plus Early Vaccination

    Drug page: Belimumab

    Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 28, 42, 56, and every 28 days thereafter through Week 32 (9 doses). Pneumococcal vaccination is administered 4 weeks prior to the first dose of belimumab.

    Also known as: BENLYSTA™

  • BiologicalBelimumab plus Late Vaccination

    Drug page: Belimumab

    Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 0, 14, 28, and then every 28 days thereafter through Week 28 (9 doses). Pneumococcal vaccination is administered 24 weeks after the first dose of belimumab.

    Also known as: BENLYSTA™

06

What researchers measure

Primary outcomes

  1. Number of Participants With Positive Antibody Responses to at Least One of the 23 Pneumococcal Vaccine Serotypes 4 Weeks Post-vaccination

    A positive immune response to at least one pneumococcal serotype is defined as a 2-fold or greater increase from pre-vaccination levels. For unquantifiable pre-vaccination antibody levels, a positive antibody response was considered as a post-vaccination level \>=0.6 micrograms (µg)/milliliter (mL). Post-vaccination pneumococcal titers were assessed on Day 28 (Week 4) prior to the first dose of belimumab in the early cohort and on Day 196 (Week 28) prior to the last belimumab dose in the late cohort. Evaluable participants for the early cohort included those who received the vaccination at Day 0 and had titers drawn at Week 4. For the late cohort, evaluable participants received at least 5 of the 7 doses of belimumab up through Week 24, received the vaccination at Week 24, and had titers drawn at Week 28.

    Time frame: Four weeks after vaccination

07

Results

Posted Jul 25, 2016

Participant flow

Eligible participants with systemic lupus erythematosus (SLE) were randomized in 7:9 ratio to receive pneumonococcal vaccination either 4 weeks prior (early cohort) or 24 weeks after (late cohort) their first belimumab dose of 10 milligram (mg)/kilogram (kg) intravenously (IV).

Participant flow — Overall Study
MilestoneBelimumab Plus Early VaccinationBelimumab Plus Late Vaccination
Started3445
Completed2841
Not completed64
Withdrew: Withdrawal by subject12
Withdrew: Adverse event30
Withdrew: Lost to follow-up02
Withdrew: Other reason20

Outcome measures

PrimaryNumber of Participants With Positive Antibody Responses to at Least One of the 23 Pneumococcal Vaccine Serotypes 4 Weeks Post-vaccination

A positive immune response to at least one pneumococcal serotype is defined as a 2-fold or greater increase from pre-vaccination levels. For unquantifiable pre-vaccination antibody levels, a positive antibody response was considered as a post-vaccination level \>=0.6 micrograms (µg)/milliliter (mL). Post-vaccination pneumococcal titers were assessed on Day 28 (Week 4) prior to the first dose of belimumab in the early cohort and on Day 196 (Week 28) prior to the last belimumab dose in the late cohort. Evaluable participants for the early cohort included those who received the vaccination at Day 0 and had titers drawn at Week 4. For the late cohort, evaluable participants received at least 5 of the 7 doses of belimumab up through Week 24, received the vaccination at Week 24, and had titers drawn at Week 28.

Time frame:
Four weeks after vaccination
Reported as:
Number · Participants
Number of Participants With Positive Antibody Responses to at Least One of the 23 Pneumococcal Vaccine Serotypes 4 Weeks Post-vaccination
ParticipantsBelimumab Plus Early VaccinationBelimumab Plus Late Vaccination
Number of Participants With Positive Antibody Responses to at Least One of the 23 Pneumococcal Vaccine Serotypes 4 Weeks Post-vaccination3240

Adverse events

Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until follow-up (up to 8 weeks following administration of the last dose of belimumab).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Belimumab Plus Early Vaccination—4/34 (11.8%)21/34 (61.8%)
Belimumab Plus Late Vaccination—3/45 (6.7%)32/45 (71.1%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventBelimumab Plus Early VaccinationBelimumab Plus Late Vaccination
Any eventCardiac disorders2/341/45
Any eventRenal and urinary disorders2/340/45
Any eventPsychiatric disorders0/342/45
Cardiac failure congestiveCardiac disorders1/340/45
Pericarditis lupusCardiac disorders1/340/45
Chronic kidney diseaseRenal and urinary disorders1/340/45
Glomerulonephritis proliferativeRenal and urinary disorders1/340/45
Any eventInvestigations1/340/45
Transaminases increasedInvestigations1/340/45
Any eventMetabolism and nutrition disorders1/340/45
Most frequent other events
Showing 10 of 22
Most frequent other events
EventBelimumab Plus Early VaccinationBelimumab Plus Late Vaccination
Any eventInfections and infestations10/3420/45
Any eventGastrointestinal disorders7/3412/45
Any eventMusculoskeletal and connective tissue disorders6/3411/45
ArthralgiaMusculoskeletal and connective tissue disorders6/3410/45
NauseaGastrointestinal disorders6/349/45
Any eventNervous system disorders5/345/45
Gastroenteritis viralInfections and infestations1/346/45
DizzinessNervous system disorders4/342/45
Any eventRespiratory, thoracic and mediastinal disorders4/343/45
CoughRespiratory, thoracic and mediastinal disorders4/343/45

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Belimumab Plus Early VaccinationBelimumab Plus Late VaccinationTotal
Mean41.0 ± 12.5738.6 ± 12.3139.6 ± 12.40
Sex: Female, Male
Sex: Female, Male(Participants)Belimumab Plus Early VaccinationBelimumab Plus Late VaccinationTotal
Female294372
Male527
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Belimumab Plus Early VaccinationBelimumab Plus Late VaccinationTotal
White252752
Black or African American81220
Asian145
Native Hawaiian or Other Pacific Islander011
Mixed Race011
08

Study locations

15 sites
  • GSK Investigational Site
    Birmingham, Alabama 35249, United States
  • GSK Investigational Site
    Paradise Valley, Arizona 85253, United States
  • GSK Investigational Site
    Shreveport, Louisiana 71103, United States
  • GSK Investigational Site
    Baltimore, Maryland 21201, United States
  • GSK Investigational Site
    Cumberland, Maryland 21502, United States
  • GSK Investigational Site
    Hagerstown, Maryland 21740, United States
  • GSK Investigational Site
    New York, New York 10016, United States
  • GSK Investigational Site
    Toledo, Ohio 43623, United States
  • GSK Investigational Site
    Duncansville, Pennsylvania 16635, United States
  • GSK Investigational Site
    Austin, Texas 78731, United States
  • GSK Investigational Site
    Austin, Texas 78758, United States
  • GSK Investigational Site
    Houston, Texas 77090, United States
  • GSK Investigational Site
    Burlington, Vermont 05401, United States
  • GSK Investigational Site
    Seattle, Washington 98133, United States
  • GSK Investigational Site
    Spokane, Washington 99204, United States
09

References and documents

Publications

  • Azoicai T, Antoniu S, Caruntu ID, Azoicai D, Antohe I, Gavrilovici C. Belimumab and antipneumococcal vaccination in patients with systemic lupus erythematosus. Expert Rev Clin Immunol. 2018 Mar;14(3):175-177. doi: 10.1080/1744666X.2018.1429269. Epub 2018 Jan 22. PubMed 29336179 ↗

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2012 to primary completion in Sep 2015, 39 months.

Results were first posted in Jul 2016, 10 months after primary completion.

Of 33 phase 4 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 42. This study's 39 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2012
First posted
May 14, 2012
StartActual
May 31, 2012
Primary completionActual
Sep 1, 2015
CompletionActual
Sep 24, 2015
Results first posted
Jul 25, 2016
Last update
Aug 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01597492
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 14, 2012
Start date
May 31, 2012
Primary completion
Sep 1, 2015
Completion
Sep 24, 2015
Results posted
Jul 25, 2016
Last update
Aug 16, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion